Get started
Author

Kristen Sweet

Observed names: K Sweet, K. Sweet, Kristen M. Sweet, Kristen Marie Sweet, Sweet, K
Observed institutions: Johnson & Johnson (United States), University of Rochester Medicine, Beyond Celiac, Janssen Research & Development (United States), University of Glasgow, University of Pennsylvania
ORCID: 0000-0001-9825-003X
Observed ORCID: 0000-0001-9825-003X
OpenAlex ID: A5114073147
Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
2018 · Atul Deodhar, Lianne S. Gensler, et al. · Arthritis & Rheumatology · 335
PDF
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies
2021 · Philip J Mease, Philip S Helliwell, et al. · The Lancet Rheumatology · 106
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
2020 · Philip S Helliwell, Dafna D Gladman, et al. · RMD Open · 66
PDF
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
2021 · Kristen Sweet, Qingxuan Song, et al. · RMD Open · 38
PDF
Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
2022 · Georg Schett, Matthew J. Loza, et al. · Rheumatology and Therapy · 30
PDF
Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus
2020 · Matteo Cesaroni, Loqmane Seridi, et al. · Arthritis & Rheumatology · 26
PDF
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials
2023 · Arthur Kavanaugh, Xenofon Baraliakos, et al. · Advances in Therapy · 20
PDF
Responsiveness of Serum C‐Reactive Protein, Interleukin‐17A, and Interleukin‐17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Double‐Blind, Placebo‐Controlled Trials
2019 · Stefan Siebert, Kristen Sweet, et al. · Arthritis & Rheumatology · 20
PDF
Gluten-induced Neurocognitive Impairment
2021 · Jessica B. Edwards George, Babatunde Aideyan, et al. · Journal of Clinical Gastroenterology · 18
Thu0052 Ustekinumab and Guselkumab Treatment Results in Differences in Serum Il17a, Il17f and Crp Levels in Psoriatic Arthritis Patients: a Comparison From Ustekinumab Ph3 and Guselkumab Ph2 Programs
2019 · Stefan Siebert, Matthew J Loza, et al. · Annals of the Rheumatic Diseases · 12
PDF
Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials
2023 · Stefan Siebert, Kristen M. Sweet, et al. · ACR Open Rheumatology · 4
PDF
Pos0195 Guselkumab Treatment Modulates Core Psoriatic Arthritis Gene Expression in Two Phase 3 Clinical Trials (discover-1 and -2)
2021 · S. Siebert, K. Sweet, et al. · Annals of the Rheumatic Diseases · 4
Energy Trial in Warm Autoimmune Hemolytic Anemia (wAIHA): Design of a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Blocker
2022 · Irina Murakhovskaya, Bruno Fattizzo, et al. · Blood · 3
Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial
2019 · Kristen Sweet, Bidisha Dasgupta, et al. · Annals of the Rheumatic Diseases · 3
Discovery of prognostic and treatment predictive biomarkers in recently diagnosed type 1 diabetes patients treated with anti TNFα
2023 · S Kostense, Jaco M Klap, et al. · medRxiv · 2
PDF
Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the P19 Subunit of Il-23, on Axial-related Endpoints in Patients With Active Psa With Imaging-confirmed Sacroiliitis: Week-52 Results From Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies
2021 · Rafael Tomaz Gomes, Philip Mease, et al. · Congresso Brasileiro de Reumatologia · 2
PDF
Op0161 Association of Baseline Cytotoxic Gene Expression With Ustekinumab Response in Systemic Lupus Erythematosus
2020 · L. Seridi, M. Cesaroni, et al. · Annals of the Rheumatic Diseases · 2
PDF
Op0278 Biomarker Profiling Reveals Novel Mechanistic Insights Into Ustekinumab Therapeutic Responses in Systemic Lupus Erythematosus
2019 · Matteo Cesaroni, Loqmane Seridi, et al. · Annals of the Rheumatic Diseases · 2
PDF
FRI0243 Sirukumab treatment reduces levels of iron-regulatory proteins and ameliorates inflammation-associated anemia in rheumatoid arthritis patients
2017 · M Loza, K Campbell, et al. · Annals of the Rheumatic Diseases · 2
PDF
Publisher Correction to: Collagen Turnover Biomarkers Associate with Active Psoriatic Arthritis and Decrease with Guselkumab Treatment in a Phase 3 Clinical Trial (DISCOVER-2)
2022 · Georg Schett, Matthew J. Loza, et al. · Rheumatology and Therapy · 1
PDF
Pos1036 Collagen Turnover Markers Are Associated With Active Psoriatic Arthritis and Decrease With Guselkumab Treatment in a Phase-3 Clinical Trial
2021 · G. Schett, M.J. Loza, et al. · Annals of the Rheumatic Diseases · 1
PDF
Op0229 Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (discover-1 and Discover-2)
2020 · S. Siebert, I. Mcinnes, et al. · Annals of the Rheumatic Diseases · 1
PDF
251 Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus
2019 · Jarrat Jordan, Kristen Sweet, et al. · Lupus Science & Medicine · 1
PDF
OP0103 The effect of sirukumab plus methotrexate on circulating biomarkers of joint destruction in moderate to severe rheumatoid arthritis patients from the sirround-d phase 3 study
2017 · B Dasgupta, K Campbell, et al. · Annals of the Rheumatic Diseases · 1
PDF
Nipocalimab for warm autoimmune hemolytic anemia: results from the phase 2/3 randomized, double-blind ENERGY study
2026 · Bruno Fattizzo, Irina Murakhovskaya, et al. · Blood
Works count: 31
Citation count: 701
H-index: 10
I10-index: 10
Year
Topic
Type